Search

Search Results

• CO-62 | ACCESS TO ULTRA-LONG HALF-LIFE FACTOR VIII AS THE DEFINITIVE MOTIVATION FOR IMMUNE TOLERANCE INDUCTION IN THE ERA OF NON-REPLACEMENT THERAPIES B. Borsellino¹, T. Martini¹, I. Ricca², C. Linari³, B. Pollio¹ | ¹Paediatric Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital "Città della Salute e della Scienza", Torino, Italy; ²Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; ³Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy

  Beatrice Borsellino

  14-10-2026

  https://doi.org/10.4081/btvb.2026.672

  0

  PDF: 0

• CO-02 | NEONATAL GENOMIC SCREENING ENABLES PRE-SYMPTOMATIC DIAGNOSIS AND PREVENTIVE MANAGEMENT OF HEMOPHILIA B. Borsellino¹, B. Pollio¹, P. Quarello^2|3, T. Martini¹, C. Linari⁴, M. Carabotta⁵, C. Cagnazzo², S. Minucci⁶, F. Fagioli^2|3 | ¹Paediatric Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital "Città della Salute e della Scienza", Torino, Italy; ²Paediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children’s Hospital, Torino, Italy; ³Department of Paediatric and Public Health Sciences, University of Turin, Italy; ⁴Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy; ⁵Department of Pediatrics, G. d'Annunzio University, Chieti, Italy; ⁶Italian Institute for Genomic Medicine, IRCCS, Candiolo, Italy

  Beatrice Borsellino

  14-10-2026

  https://doi.org/10.4081/btvb.2026.612

  0

  PDF: 0

• CO-59 | CONCIZUMAB IN A YOUNG CHILD WITH SEVERE HEMOPHILIA B WITH INHIBITOR: EFFECTIVE BLEED CONTROL AND SAFE HOME MANAGEMENT T. Martini¹, B. Borsellino^1|2, B. Pollio¹ | ¹Hemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.669

  0

  PDF: 0

• BEST-08 | PERIOPERATIVE MANAGEMENT OF CHILDREN WITH MILD FACTOR VII DEFICIENCY UNDERGOING SURGERY: A RETROSPECTIVE COHORT STUDY B. Borsellino¹, T. Martini¹, I. Ricca², B. Pollio¹ | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Transfusion Medicine, Ivrea Hospital, Ivrea, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.608

  0

  PDF: 0

• CO-58 | SUCCESSFUL TREATMENT WITH EFANESOCTOCOG ALFA OF INTRACRANIAL HEMORRHAGE IN A NEWBORN AFFECTED BY SEVERE HEMOPHILIA A T. Martini¹, B. Borsellino^1|2, B. Pollio¹ | ¹Hemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.668

  0

  PDF: 0

• BEST-02 | PERIOPERATIVE BLEEDING IN CHILDREN WITH LOW VON WILLEBRAND FACTOR UNDERGOING ADENOID AND TONSIL SURGERY: A 15-YEAR SINGLE-CENTER EXPERIENCE T. Martini¹, B. Borsellino^1|2, B. Pollio¹ | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.602

  0

  PDF: 1

• CO-47 | JOINT ULTRASOUND FOLLOW-UP IN PEDIATRIC PATIENTS WITH HEMOPHILIA: A 12-YEAR PROSPECTIVE SINGLE-CENTER EXPERIENCE I. Ricca¹, B. Borsellino^2|3, T. Martini², C. Martinoli⁴, B. Pollio² | ¹Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; ²Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ³Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy; ⁴Department of Health Science DISSAL, University of Genova, Unit of Radiology and IRCCS San Martino Hospital, Genova, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.657

  0

  PDF: 0

• CO-35 | TRANSITION FROM A PAEDIATRIC REFERRAL CENTER TO AN ADULT CENTER IN INHERITED BLEEDING DISORDERS: A REAL-WORLD COHORT STUDY I. Ricca¹, A. Casson¹, T. Martini², B. Borsellino², A. Barchieri¹, G. Guido¹, P. Ocello¹, M. Tucciarone¹, R. Albiani², B. Pollio², G. Delios¹ | ¹Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Italy; ²Centro Esperto Malattie Emorragiche Congenite in Età Pediatrica e della Donna in Gravidanza - SSD Medicina Trasfusionale Materno-Infantile e Traumatologica, Città della Salute e della Scienza di Torino, Italy

  Irene Ricca

  14-10-2026

  https://doi.org/10.4081/btvb.2026.645

  0

  PDF: 0

• CO-77 | PERINATAL MANAGEMENT IN WOMAN WITH MILD HEMOPHILIA B: A TWIN PREGNANCY CASE T. Martini¹, B. Borsellino^1|2, B. Pollio¹ | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.687

  0

  PDF: 0

• CO-21 | FUSION 2: VALIDATION AND CLINICAL PERFORMANCE OF AN INTEGRATED ULTRASOUND–FUNCTIONAL ASSESSMENT SYSTEM IN HEMOPHILIA M.E. Susi¹, E.A. Boccalandro², A. Giuffrida³, I. Ricca⁴, P. Imazio⁵, E. Bonetti⁶, I. Nichele⁷ B. Pollio⁸, E. Zanon⁹, E. Baldacci¹⁰, C. Santoro¹⁰, G. Delios⁴, S. Ligia¹⁰, M. Biglietto¹⁰, I. Calcaterra¹¹, M. Napolitano¹², M. Bodini², C. Simion⁹, B. Borsellino⁸, G. Pasta¹³, M.N.D. Di Minno¹¹, C. Martinoli^14|15 | ¹DIMES, Department of Experimental Medicine, University of Genoa, Italy; ²Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy; ³Hemophilia Center, Borgo Roma Hospital, Integrated University Hospital of Verona, Italy; ⁴Immunology and Transfusion Medicine Service, Hemophilia Center, Ivrea Hospital, Local Health Authority TO4, Ivrea, Italy; ⁵Rehabilitation and Functional Recovery Service, Pediatric Orthopedics Unit, Regina Margherita Children’s Hospital, City of Health and Science University Hospital of Turin, Italy; ⁶Pediatric Oncohematology Unit, Borgo Trento Hospital, Integrated University Hospital of Verona, Italy; ⁷Haemophilia and Thrombosis Center, Haematology Department, San Bortolo Hospital, Vicenza, Italy; ⁸Transfusion Medicine and Immunohematology Service, Regina Margherita Children’s Hospital, City of Health and Science University Hospital of Turin, Italy; ⁹Coagulation Disorders and Hemophilia Center, University Hospital of Padova, Italy; ¹⁰Unit of Special Diagnosis and Therapy of Hemostasis and Thrombosis, Hematology Department, Policlinico Umberto I, Sapienza University of Rome, Italy; ¹¹Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Federico II University, Napoli, Italy; ¹²Dipartimento PROMISE, Università degli Studi di Palermo and UOC Ematologia e Malattie Rare, PO “Cervello”, Palermo, Italy; ¹³Orthopedics and Traumatology Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy; ¹⁴DISSAL, Department of Health Sciences, University of Genoa, Italy; ¹⁵UOC Emergency and Musculoskeletal Radiology, IRCCS AOM San Martino Hospital, Genova, Italy

  Maria Elena Susi

  14-10-2026

  https://doi.org/10.4081/btvb.2026.631

  0

  PDF: 0

• CO-66 | PREGNANCY OUTCOMES AND PERIPARTUM MANAGEMENT IN WOMEN WITH CONGENITAL FIBRINOGEN DISORDERS: A SINGLE-CENTRE EXPERIENCE T. Martini¹, B. Borsellino^1|2, B. Pollio¹ | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.676

  1

  PDF: 0

• CO-20 | REAL-WORLD EXPERIENCE ON THE MANAGEMENT OF MILD HEAD INJURY IN A COHORT OF CHILDREN WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS TREATED WITH EMICIZUMAB B. Pollio¹, B. Borsellino^1|2, T. Martini¹ | ¹Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; ²Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy

  Tiziano Martini

  14-10-2026

  https://doi.org/10.4081/btvb.2026.630

  1

  PDF: 0